Condition: Hereditary Spastic Paraplegia Type 50 · Sponsor: Elpida Therapeutics SPC
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
This description comes directly from the study's public registry record.
Rachel Thomas · +1-833-335-7432 · studyinfo@elpidatx.com
Always discuss trial participation with your own doctor first.
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Sant Joan de Deu | Barcelona, Spain | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06692712